OncoMatch/Clinical Trials/NCT06902272
ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer
Is NCT06902272 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Platinum Doublet Chemotherapy for non small cell lung cancer.
Treatment: Pembrolizumab · Platinum Doublet Chemotherapy — The purpose of this study is to determine if a blood test called circulating tumor DNA (ctDNA) can be used to predict how well patients will respond to treatment and if there is any cancer left after surgery. The investigators will also study if a drug called pembrolizumab can help prevent the cancer from coming back in patients who are ctDNA-positive or who have evidence of cancer after treatment and surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Biomarker criteria
Required: ALK wild-type
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Required: EGFR wild-type
Disease stage
Required: Stage IB (≥4 CM), II, IIIB (N2) (8th American Joint Committee on Cancer (AJCC))
Excluded: Stage LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC DISEASE
Stage IB (≥4 cm), II, or IIIB (N2) NSCLC (as per the 8th American Joint Committee on Cancer (AJCC)) who are considered resectable
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Previous exposure to anti-cancer therapy, including chemotherapy, radiotherapy or immunotherapy
Cannot have received: radiation therapy
Previous exposure to anti-cancer therapy, including chemotherapy, radiotherapy or immunotherapy
Cannot have received: immunotherapy
Previous exposure to anti-cancer therapy, including chemotherapy, radiotherapy or immunotherapy
Cannot have received: immunosuppressive drugs
previous exposure to immunosuppressive drugs within 3 weeks before neoadjuvant treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami · Miami, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify